Denali Therapeutics prices $275M public offering of 10.4M shares at $26.50/share

Denali Therapeutics Inc.

Priced 10,377,359 shares of common stock at $26.50 per share for gross proceeds of ~$275M.
Underwriters granted 30-day option to purchase up to an additional 1,556,603 shares.
Gross proceeds would be ~$316.2M if option exercised in full.
Offering expected to close on or about October 24, 2022, subject to closing conditions.
Goldman Sachs, J.P. Morgan, and Jefferies are joint book-running managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.